Clearpoint Neuro
Logotype for Clearpoint Neuro Inc

Clearpoint Neuro (CLPT) investor relations material

Clearpoint Neuro Registration filing summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Clearpoint Neuro Inc
Registration filing summary18 Nov, 2026

Company overview and business model

  • Commercial-stage medical-device business spanning minimally invasive neurosurgery, neurocritical care and biologics/drug-delivery services for pharmaceutical and biotech partners.

  • ClearPoint system guides electrode, biopsy-needle and laser-catheter placement and brain infusions; SmartFrame OR and 2025 navigation software support operating-room procedures.

  • IRRAflow, added through the 2025 IRRAS acquisition, combines intracranial irrigation, drainage and pressure monitoring; ClearPoint Prism is commercialized under exclusive global neuro rights from Clinical Laserthermia Systems AB.

  • More than 60 biologics and drug-delivery customers are evaluating products or services for brain gene- and cell-therapy trials; FDA authorized SmartFlow cannula marketing for an AADC gene therapy in 2024.

Financial performance and metrics

  • Net tangible book value at September 30, 2026 was $7.4m, or $0.23/share; illustrative post-offering value was $104.0m, or $2.37/share, assuming $100m gross proceeds at $8.48/share.

  • Under that illustration, new investors face $6.11/share immediate dilution; existing shares were 32,051,494 at September 30, 2026, excluding 2,497,985 option/RSU shares and 1,724,125 shares available for future awards.

Use of proceeds and capital allocation

  • ATM net proceeds, if any, are intended for general corporate purposes, including working capital, capex, R&D, clinical trials, commercialization, acquisitions, in-licensing and complementary investments; management retains broad discretion.

  • Pending use, proceeds may be invested in short-term interest-bearing obligations, investment-grade instruments, certificates of deposit or direct or guaranteed U.S. government obligations.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Clearpoint Neuro earnings date

Logotype for Clearpoint Neuro Inc
Q4 20265 Mar, 2027
Clearpoint Neuro
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Clearpoint Neuro earnings date

Logotype for Clearpoint Neuro Inc
Q4 20265 Mar, 2027

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

ClearPoint Neuro, Inc. operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under direct, and intra-procedural magnetic resonance imaging guidance. It offers ClearPoint software, a platform that provides direct visualization of MRI that enables physicians to image the patient's brain in real-time;